45 / 74 · 0:54 · Original AXON film
Tirzepatide
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
A direct comparison
Comparing medicines is more informative when they are tested within the same trial. SURMOUNT-5 directly compared tirzepatide with semaglutide in adults with obesity. [1]
SURMOUNT-5 | open-label trial
The 2025 randomized study enrolled 751 participants without type two diabetes and followed treatment for 72 weeks. Participants and researchers knew the assigned medicine. [1]
Weight and waist outcomes
Tirzepatide produced a larger average reduction in body weight and waist circumference under the tested conditions. Gastrointestinal adverse events were common in both groups. [1]
One comparison, defined scope
This comparison answers a specific weight-management question. It does not identify the best choice for every person or compare every formulation, health outcome, or long-term risk. [1]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Aronne et al. (2025): Tirzepatide as Compared with Semaglutide for the Treatment of Obesity →Open-label design, population, sample size, duration, weight/waist outcomes, and gastrointestinal adverse events.
